Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Rationale: Increasing frequency of human exposure to PEG-related products means that healthy people are likely to have pre-existing anti-PEG antibodies (pre-αPEG Ab).However, the influence of pre-αPEG Abs on the pharmacokinetics (PK) and therapeutic efficacy of LipoDox is unknown.Methods: We generated two pre-αPEG Ab mouse models.First, naïve mice were immunized with PEGylated protein to generate an endogenous αPEG Ab titer (endo αPEG).Second, monoclonal αPEG Abs were passively transferred (αPEG-PT) into naïve mice to establish a αPEG titer.The naïve, endo αPEG and αPEG-PT mice were intravenously injected with 111 in-labeled LipoDox to evaluate its PK.Tumor-bearing naïve, endo αPEG and αPEG-PT mice were intravenously injected with 111 in-labeled LipoDox to evaluate its biodistribution.The therapeutic efficacy of LipoDox was estimated in the tumor-bearing mice.Results: The areas under the curve (AUC)last of LipoDox in endo αPEG and αPEG-PT mice were 11.5-and 15.6-fold less, respectively, than that of the naïve group.The biodistribution results suggested that pre-αPEG Ab can significantly reduce tumor accumulation and accelerate blood clearance of 111 In-labeled LipoDox from the spleen.The tumor volumes of the tumor-bearing endo αPEG and αPEG-PT mice after treatment with LipoDox were significantly increased as compared with that of the tumor-bearing naïve mice.Conclusions: Pre-αPEG Abs were found to dramatically alter the PK and reduce the tumor accumulation and therapeutic efficacy of LipoDox.Pre-αPEG may have potential as a marker to aid development of personalized therapy using LipoDox and achieve optimal therapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 1×
“PEG alternatives such as chitosan, XTEN peptide, poly(carboxybetaine), poly(glycerol) and poly(2-oxazaline) molecules have been used in drug modification, which enhanced serum half-life and had good biocompatibility [34-37].”
BackgroundArmstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541 · cited 1×
“PEGylation also enhances the enhanced permeability and retention (EPR) effect of liposomal doxorubicin (Doxil/Caelyx/LipoDox) that is used to treat ovarian and breast carcinomas and Kaposi’s sarcoma [3-5], and a PEG-micelle drug (Genexol-PM) is currently undergoing phase I/II clinical trials for treatment of lung canc…”
BackgroundWang, X., Ishida, T., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.010 · Cited by 421
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
Cited by
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
“Consequently, many patients have previously been exposed to PEG, resulting in the detection of anti-PEG antibodies in human blood prior to the administration of PEGylated drugs/NPs (Figure 2b,c) [44,53,54].”
BackgroundChen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Self-citationPEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 294
Metadata
- Authors
- Hsieh, Y.-C., Wang, H.-E., Lin, W.-W., Roffler, S. R., Cheng, T.-C., Su, Y.-C., Li, J.-J., Chen, C.-C., Huang, C.-H., Chen, B.-M., Wang, J.-Y., Cheng, T.-L., & Chen, F.-M.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 11
- Pages
- 3164-3175
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2807009021
- Cited by
- 108
- References
- 5
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.